ProQR Reports Increased 2025 Net Loss, €92.4M Cash with Runway into Mid-2027, Advances Key Pipeline Programs

summarizeSummary

ProQR Therapeutics reported its full-year 2025 financial results, including an increased net loss, but highlighted a cash runway into mid-2027 and significant progress across its RNA editing pipeline, including two new development candidates and a near-term clinical data readout.

check_boxKey Events

• Full Year 2025 Financial Results

  ProQR reported a net loss of €42.2 million (€0.40 per diluted share) for the year ended December 31, 2025, an increase from €27.8 million in 2024. Net cash used in operating activities increased to €52.8 million from €36.4 million in the prior year.

• Strong Cash Position and Runway

  The company ended 2025 with €92.4 million in cash and cash equivalents, down from €149.4 million at the end of 2024, but confirmed a cash runway into mid-2027.

• Pipeline Advancement and Catalysts

  AX-0810 for cholestatic diseases is progressing in a Phase 1 study, with target engagement data expected in the first half of 2026. Two new Development Candidates, AX-2402 for Rett syndrome and AX-2911 for MASH, were selected based on strong preclinical data.

• Eli Lilly Collaboration Milestones

  ProQR achieved $4.5 million in milestones from its collaboration with Eli Lilly in 2025, with expectations for continued execution and potential additional milestone payments in 2026.

auto_awesomeAnalysis

This filing provides a comprehensive update on ProQR's financial performance and significant pipeline advancements. While the company reported an increased net loss and higher cash burn for 2025, the €92.4 million in cash and cash equivalents provides a runway into mid-2027, which is crucial for a clinical-stage biotech. The progress of AX-0810 towards target engagement data in 1H 2026 and the selection of two new development candidates (AX-2402 for Rett syndrome and AX-2911 for MASH) demonstrate active pipeline development and future catalysts. The continued achievement of milestones in the Eli Lilly collaboration also provides non-dilutive funding and external validation.